Gilead Gilead aims to challenge GSK's HIV drug Tivicay But GSK hit back with plans for two-drug regimen.
News Can Gilead find another Pharmasset in 2017? Company needs to make acquisition to grow, admits CEO.
News New Gilead and AbbVie hepatitis C combos filed in EU Companies aim to cut treatment time and side effects.
News Pharma criticises 'heavy handed' NICE affordability test NHS England and NICE are attempting to reduce budget impact of drugs.
Views & Analysis The future of healthcare: the patient advocate and investor ... Examining the views of different stakeholders in the ecosystem supporting drug R&D.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
